{
    "clinical_study": {
        "@rank": "134397", 
        "arm_group": {
            "arm_group_label": "HBeAg-negative Chronic Hepatitis B", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is an expanded access programme to make Pegasys (peginterferon alfa-2a) available to\n      patients with HBeAg-negative chronic hepatitis B in Morocco. Patients will receive Pegasys\n      180 mcg subcutaneously weekly for 48 weeks and efficacy and safety will be recorded during\n      treatment and for 24 weeks of follow-up."
        }, 
        "brief_title": "An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 and </= 70 years of age\n\n          -  HBeAg-negative chronic hepatitis B\n\n          -  HBsAg-positive for at least 6 months, anti-HBs negative\n\n          -  Serum alanine transaminase (ALT) > 2 ULN (upper limit of normal) but </= 10 x ULN\n\n          -  HBV DNA > 10'000 copies/ml (Roche Monitor or Taqman)\n\n          -  No previous treatment with interferon (standard or pegylated) or with a nucleoside\n             analogue\n\n          -  Women of childbearing potential must agree to use reliable contraception during the\n             study and for 3 months after treatment completion\n\n        Exclusion Criteria:\n\n          -  Previous antiviral interferon-based therapy for chronic hepatitis B\n\n          -  Pregnant and lactating women\n\n          -  Evidence of decompensated liver disease\n\n          -  Co-infection with active hepatitis A, hepatitis C, hepatitis D and/or human\n             immunodeficiency virus (HIV)\n\n          -  History or other evidence of a medical condition associated with chronic liver\n             disease other than viral hepatitis\n\n          -  Previous or current hepatocellular carcinoma\n\n          -  History or other evidence of bleeding from oesophageal varices or other conditions\n             consistent with decompensated liver disease\n\n          -  Inadequate hematologic or renal function\n\n          -  Serum bilirubin level > 2 times the upper limit of normal\n\n          -  Severe psychiatric disease\n\n          -  History of severe seizure disorder or current anticonvulsant use\n\n          -  History of evidence of any disease or condition which would make the patient, in the\n             opinion of the investigator, unsuitable for the study\n\n          -  Evidence of drug abuse within one year of study entry\n\n          -  Alcohol intake of more than 3 standard drinks per day for men and 2 standard drinks\n             per day for women (1 standard drink contains 10 g of alcohol)\n\n          -  Participation in another trial or receipt of an investigational drug within 12 weeks\n             prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787279", 
            "org_study_id": "ML19522"
        }, 
        "intervention": {
            "arm_group_label": "HBeAg-negative Chronic Hepatitis B", 
            "description": "180 mcg subcutaneously weekly, 48 weeks", 
            "intervention_name": "peginterferon alfa-2a [Pegasys]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Casablanca", 
                        "country": "Morocco"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Casablanca", 
                        "country": "Morocco", 
                        "zip": "20100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rabat", 
                        "country": "Morocco", 
                        "zip": "504"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rabat", 
                        "country": "Morocco", 
                        "zip": "62000"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Morocco"
        }, 
        "number_of_arms": "1", 
        "official_title": "Expanded Access Programme of PEGASYS\u00ae (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-negative Chronic Hepatitis B", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Morocco: Ministry of Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of patients achieving HCV DNA <10'000 copies/ml (Roche PCR or Taqman tests)", 
                "safety_issue": "No", 
                "time_frame": "approximately 6 years"
            }, 
            {
                "measure": "Percentage of patients achieving normalization of alanine aminotransferase (ALT)", 
                "safety_issue": "No", 
                "time_frame": "approximately 6 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 6 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787279"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients achieving HBV DNA < 400 copies/ml (Roche PCR or Taqman tests)", 
                "safety_issue": "No", 
                "time_frame": "approximately 6 years"
            }, 
            {
                "measure": "Percentage of patients achieving HBsAg seroconversion (HBsAg-negative, anti-HBs positive)", 
                "safety_issue": "No", 
                "time_frame": "approximately 6 years"
            }, 
            {
                "measure": "Percentage of patients achieving combined response (HBV DNA < 10'000 copies/ml and normal ALT)", 
                "safety_issue": "No", 
                "time_frame": "approximately 6 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2006", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}